RxDoctor Payments Data

Katie Grubb, APRN

Nurse Practitioner · East Bernstadt, KYNPI 1962808048

Payments from drug & device makers

$6,009in general payments, 2019–2025

Across 250 payments — averaging $24.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$933
  • Lilly USA, LLC$819
  • Esperion Therapeutics, Inc.$448
  • AbbVie$313
  • GSK$285
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$6,009100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,009 in reported general payments places this provider in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$40,613
Medicare patients
130
Services billed
1,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide144$152,549
OzempicSemaglutide127$145,552
Breztri AerosphereBudesonide/Glycopyr/Formoterol70$43,657
FarxigaDapagliflozin Propanediol41$38,261
JardianceEmpagliflozin31$37,381
EliquisApixaban29$27,021
JanuviaSitagliptin Phosphate25$19,065
LinzessLinaclotide15$15,295
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,999
XareltoRivaroxaban12$6,697
Ventolin HfaAlbuterol Sulfate99$5,926
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,781
Albuterol Sulfate HfaAlbuterol Sulfate108$3,346
Levothyroxine Sodium280$3,145
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$2,637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$819$152,549144 claims
Novo NordiskOzempic$933$145,552127 claims
AstraZenecaBreztri Aerosphere, Farxiga$1,677$81,918111 claims
Boehringer IngelheimJardiance$40$37,38131 claims
PfizerEliquis$29$27,02129 claims
MerckJanuvia$29$19,06525 claims
AbbVieLinzess, Synthroid$313$17,39832 claims
GSKTrelegy Ellipta$285$8,99914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in East Bernstadt

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →